Everything you need to know about how we analyzed the 13,000+ comments submitted in the federal government’s request for ...

A campaign active since last November has been targeting Python developers building Telegram bots with trojanized Pyrogram ...

You don’t need expensive software for basic PDF tasks. In fact, all you need is a handful of free web-based apps.

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

Google has updated Gemini to generate and package downloadable files like PDFs, Word, and Excel directly in the chat. This new feature, available globally, aims to eliminate the need for manual ...

You can now ask the Gemini app to directly generate “downloadable and ready-to-share files.” Google wants you to “quickly move from a brainstorm to a complete ...

If Python developers have one consistent gripe about their beloved language, it tends to be this: Why is it so hard to take a Python program and deploy it as a standalone artifact, the way C, C++, ...

Want to correct errors or update content in a PDF? Whether you prefer a powerful, corporate-friendly solution or a basic app you can use at no cost, we're here to help you find the right PDF software ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...